### Analysts/Institutional Investor Meet/Conference Call Updates: Jubilant Ingrevia Q2 FY '26 Results

October 31, 2025 – Jubilant Ingrevia Limited recently hosted an earnings conference call to discuss its financial performance for the quarter and half-year ended September 30, 2025. The call, led by key management figures including Mr. Shyam Bhartia, Chairman, and Mr. Deepak Jain, CEO, highlighted robust growth despite challenging market conditions.

The company reported a 7% year-on-year revenue growth, driven primarily by its Specialty Chemicals division, which achieved double-digit revenue growth. The Nutrition segment also showed steady performance, while the Chemical Intermediates business recorded its highest quarterly sales in six quarters. Notably, EBITDA increased by 8% year-on-year, with profit after tax surging by 18%.

In terms of market dynamics, Jubilant Ingrevia noted a recovery in the broader chemical industry, despite pricing pressures. The pharmaceutical sector remains resilient, with growth observed in CDMO and Fine Chemicals products. The agrochemical sector is stabilizing after a period of inventory destocking, buoyed by consistent volume expansion.

Looking ahead, the company anticipates continued growth in H2 FY '26, particularly in its Specialty Chemicals and Nutrition businesses. They are on track to commence significant CDMO orders early next year, which is expected to further accelerate growth. Additionally, Jubilant Ingrevia is progressing on its new manufacturing facility in Gajraula, slated for completion by late 2026.

For detailed insights, you can access the full transcript of the conference call [here](https://www.jubilantingrevia.com/Uploads/files/19q2consfileEarningsCallTranscript.pdf).

Stay tuned for more updates as Jubilant Ingrevia continues to navigate the evolving market landscape and drive sustainable growth.